Neeraj Songara: Shelf-Stable Synthetic Blood – The Future of Emergency Transfusion?
Neeraj Songara, Resident Doctor at Dr S.N. Medical College Jodhpur, shared a post on LinkedIn:
“Shelf-Stable Synthetic Blood: The Future of Emergency Transfusion?
A promising advancement in transfusion medicine is bringing freeze-dried, shelf-stable synthetic blood closer to human trials.
Kalocyte, in collaboration with the University of Maryland, Baltimore, is developing this technology with support from DARPA.
Why does it matter?
Conventional RBCs require 1–6°C storage and a continuous cold chain—limiting blood availability in:
- Battlefield and military medicine
- Prehospital trauma care
- Rural/remote emergencies
- Disaster and mass-casualty situations
- Air evacuation and austere environments
A new approach to artificial blood
Earlier hemoglobin-based oxygen carriers faced major safety concerns because free hemoglobin can cause vasoconstriction, inflammation and organ injury.
Kalocyte’s approach aims to create synthetic microscopic cells that mimic key RBC functions, including:
- Oxygen delivery
- Hemodynamic support
- Appropriate blood-flow properties
- Hemostatic function
- Minimal immune/thrombotic reactions
- Potential ABO-independent use
The game-changing feature
The product is being developed as a freeze-dried powder designed for prolonged room-temperature storage and rapid reconstitution when required.
Freeze-dried – store at room temperature – reconstitute – transfuse
This could bring blood-substitute technology directly to the point of injury rather than requiring a refrigerated blood supply.
Potential applications
- Battlefield
- Ambulances
- Disaster zones
- Remote healthcare
- Mass casualties
- Extreme environments
Current status
This remains an investigational technology. Human trials and rigorous evaluation of oxygen delivery, hemostasis, immunogenicity, thrombosis, organ safety and clinical outcomes are still essential.
The goal is not necessarily to replace donor blood, but to bridge the critical gap between hemorrhage and definitive medical care.
From cold-chain-dependent donor blood toward rapidly deployable, shelf-stable blood substitutes.
A potentially transformative development for Transfusion Medicine and emergency care.”

Stay updated with Hemostasis Today.
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance